Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Patrick Dolezal reiterated a Buy rating on MBX Biosciences with a $91 price target, citing canvuparade's once-weekly dosing advantage over competitor Yorvipath and a large underpenetrated patient pool. Barclays also maintained a Buy rating with a $70 target.
Patrick Dolezal, an analyst from LifeSci Capital, maintained the Buy rating on MBX Biosciences, Inc.. The associated price target remains the same with $91.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Patrick Dolezal has given his Buy rating due to a combination of factors tied to MBX’s lead program, canvuparade, and its positioning in the hypoparathyroidism market. He views the once‑weekly profile as a meaningful convenience upgrade over the once‑daily standard Yorvipath, with AVAIL Phase 2 data suggesting efficacy broadly in line with the approved competitor, which should be acceptable given the dosing advantage.
He also highlights that physician feedback points to a sizeable, underpenetrated patient pool for PTH replacement, implying a large addressable opportunity as Yorvipath’s current sales may reflect only a fraction of demand. In his view, upcoming Phase 3 optimization—such as autoinjector use, a standardized starting dose, and a more comparable patient mix—could enhance canvuparade’s risk‑benefit profile, supporting the investment case and justifying maintaining a $91 price target while reiterating a Buy rating on MBX.
In another report released on June 15, Barclays also maintained a Buy rating on the stock with a $70.00 price target.